- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Great Strides Made In Developing New Medicines For Cancer
While there has been a great deal of discussion around Obamacare and the Supreme Court ruling that is expected to be announced in the near future, much progress has been made in other areas of public health that has gone largely unnoticed.
A report released earlier this month found that there are 981 medicines and vaccines currently being tested by America’s biopharmaceutical research companies to fight the various types of cancer affecting millions of patients around the world. The potential medicines, which are either in clinical trials or under review by the FDA, include 121 for lung cancer, 117 for lymphoma and 111 for breast cancer.
Read the full story: http://tinyurl.com/7x89x7f
Source: Forbes
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
